Loading…
Reported covered position: Program Support Student Trainee, Secretarial Internship Program, U.S. DOT (2020); Intern, Rep. Karen Bass (2015-2016); Extern, U.S. Attorneys Office, Central District of California (2015)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to physician payment reform. Issues related to CMS reimbursement for radiopharmaceuticals.
Source: Senate LDA
| PERRIGO COMPANY PLC |
| 9 |
| 2022–2024 |
| GRIFOLS SHARED SERVICES NORTH AMERICA, INC. | 8 | 2023–2024 |
| ALVOGEN | 6 | 2022–2023 |
| RECORDATI RARE DISEASES INC. | 5 | 2025–2026 |
| INDUCTIVEHEALTH INFORMATICS | 4 | 2023 |
| NOVO NORDISK A S | 4 | 2024–2025 |
| SUMITOMO PHARMA AMERICA, INC. | 4 | 2026 |
| EVOENDO, INC. | 3 | 2022 |
| GENETIX BIOTHERAPEUTICS INC. | 3 | 2023 |
| PHARMACOSMOS THERAPEUTICS INC. | 1 | 2022 |
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Small Biotech Innovation Act
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Pharmacists Fight Back in Medicare and Medicaid Act
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Client: URAC, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews, telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544, 118th Congress).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues pertaining to the utility and role of nuclear medicine as it relates to the goals of the White House's Cancer Moonshot. Additionally, issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141, 118th Congress).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues pertaining to the utility and role of nuclear medicine as it relates to the goals of the White House's Cancer Moonshot. Additionally, issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).
Nuclear Medicine Clarification Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815).
Nuclear Medicine Clarification Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815, 118th Congress).
Nuclear Medicine Clarification Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Tax Relief for American Families and Workers Act of 2024
Client: EXELIXIS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, and mental health at work. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, mental health parity, and health equity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Also, issues related to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544, 118th Congress).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).
PLASMA Act
Client: GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).
Department of Defense Appropriations Act, 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer Reviewed Cancer Research Program, including pertaining to the Department of Defense Appropriations Act, 2025 (S. 4921; Senate Report 118-204).
Department of Defense Appropriations Act, 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer Reviewed Cancer Research Program, including pertaining to the Department of Defense Appropriations Act, 2025 (S. 4921; Senate Report 118-204).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141, 118th Congress).
Find It Early Act
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199).
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Filing targets: SENATE
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to physician payment reform. Issues related to CMS reimbursement for radiopharmaceuticals.
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to accreditation for mental health parity, as well as compliance with federal mental health parity laws and regulations, including the Mental Health Parity and Addiction Equity Act (MHPAEA - Public Law No: 110-343).
Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to tariffs on nuclear medicines and radiopharmaceuticals.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation and the small biotech exception. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMITOMO PHARMA AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · RR
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (P.L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to the physician payment reform.
Issues related to medical research funding. Issues related to theranostics.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the United States. Issues related to drug pricing, including most favored nation (MFN) policies.
Issues related to trade and tariff policies pertaining to therapies for rare and ultra-rare diseases in the United States.
RECORDATI RARE DISEASES INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · RR
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
Issues related to improving access to needed therapies for rare and ultra-rare diseases in the U.S.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to the physician payment reform.
Issues related to medical research funding. Issues related to theranostics.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to the implementation and use of artificial intelligence in health care, including the role of accreditation.
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews, telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to the physician payment reform.
Issues related to medical research funding. Issues related to theranostics.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
Issues related to health care accreditation, telehealth, mental health parity, and Medicare Advantage plans. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to the physician payment reform.
Issues related to medical research funding. Issues related to theranostics.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541, 119th Congress).
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, and mental health at work. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, mental health parity, and health equity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back Act (H.R. 9096, 118th Congress). Also, issues related to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141, 118th Congress).
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815, 118th Congress).
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544, 118th Congress).
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · 4T
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, mental health at work, pharmacy benefit management services, specialty pharmacies, and reforms to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, mental health parity, health equity, pharmacy benefit management services, specialty pharmacies, and reforms to the Organ Procurement and Transplantation Network (OPTN), including reforms related to organ procurement organizations (OPOs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer Reviewed Cancer Research Program, including pertaining to the Department of Defense Appropriations Act, 2025 (S. 4921; Senate Report 118-204).
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815).
Issues related to Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer-Reviewed Cancer Research Program.
Issues pertaining to the utility and role of nuclear medicine as it relates to the goals of the White House's Cancer Moonshot. Additionally, issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, mental health at work, pharmacy benefit management services, specialty pharmacies, and reforms to the Organ Procurement and Transplantation Network (OPTN).
Issues related to health care accreditation, Medicare Advantage plans -- including Medicare Advantage Special Needs Plans (SNP) reviews -- telehealth, mental health parity, health equity, pharmacy benefit management services, specialty pharmacies, and reforms to the Organ Procurement and Transplantation Network (OPTN).
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, pharmacy benefit management services, and specialty pharmacies.
Issues related to health care accreditation, Medicare Advantage plans, including Medicare Advantage Special Needs Plans (SNP) reviews, telehealth, mental health parity, health equity, pharmacy benefit management services, and specialty pharmacies.
Issues related to accreditation for mental health parity, as well as compliance with federal mental health parity laws and regulations, including the Mental Health Parity and Addiction Equity Act (MHPAEA - Public Law No: 110-343).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer-Reviewed Cancer Research Program.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35).
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · RA
Issues related to access, coverage, and payment for cancer drugs.
Issues related to access, coverage, and payment for cancer drugs.
Issues related to access, coverage, and payment for cancer drugs.
AMERICAN GERIATRICS SOCIETY via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · 4T
Issues related to support for geriatric workforce enhancement and academic career award programs and basic and clinical research on medical complexity and health issues affecting older Americans at the NIA; issues related to the health care workforce and the federal response to the COVID-19 virus; and issues related to COVID-19 pandemic preparedness, telehealth, and primary care incentive payments.
Issues related to funding for research programs at the National Institute on Aging (NIA) and funding for geriatric workforce and academic career award programs at the Health Resources and Services Administration (HRSA).
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · 4A
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to R&D tax credits.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to health care accreditation, telehealth, mental health parity, Medicare Advantage plans, health equity, pharmacy benefit management services, and specialty pharmacies.
Issues related to health care accreditation, Medicare Advantage plans, including Medicare Advantage Special Needs Plans (SNP) reviews, telehealth, mental health parity, health equity, pharmacy benefit management services, and specialty pharmacies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs, as related to the Department of Defense Appropriations Act, 2024 (H.R. 4365) and the Department of Defense Appropriations Act, 2024 (S. 2587).
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to pharmacy benefit managers and the 340B Program.
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to accreditation of telehealth, mental health parity, pharmacy benefit management services, and specialty pharmacies.
Issues related to accreditation for mental health parity, as well as compliance with federal mental health parity laws and regulations, including the Mental Health Parity and Addiction Equity Act (MHPAEA - Public Law No: 110-343).
Issues related to accreditation of telehealth, mental health parity, pharmacy benefit management services, and specialty pharmacies.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing, related to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (H.R. 4368), and the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (S. 2131).
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs, as related to the Department of Defense Appropriations Act, 2024 (H.R. 4365) and the Department of Defense Appropriations Act, 2024 (S. 2587).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to CMS coverage of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN GERIATRICS SOCIETY via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Physician reimbursement reductions, sequestration issues, and incentives for advanced alternative payment model participation.
Support for geriatric workforce enhancement and academic career award programs and basic and clinical research on medical complexity and health issues affecting older Americans at the NIA; policy issues related to the health care workforce and the federal response to the COVID-19 virus; and policy issues related to COVID-19 pandemic preparedness, telehealth, and primary care incentive payments.
Funding for research programs at the National Institute on Aging (NIA) and funding for geriatric workforce and academic career award programs at the Health Resources and Services Administration (HRSA).
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to R&D tax credits.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
INDUCTIVEHEALTH INFORMATICS via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to disease surveillance and pandemic preparedness, and the Pandemic All-Hazards Preparedness (PAHPA) reauthorization, including the Pandemic and All-Hazards Preparedness and Response Act (S. 2333), the Preparing for All Hazards and Pathogens Reauthorization Act (H.R. 4421), and the Preparedness and Response Reauthorization Act (H.R. 4420).
Issues related to disease surveillance and pandemic preparedness, including pertaining to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 (S. 2624).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Utility of nuclear medicine at the Congressionally Directed Medical Research Programs.
Senate and House Appropriations Committees report language on nuclear medicine event reporting. Department of Defense Congressionally Directed Medical Research Programs.
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to pharmacy benefit managers and the 340B program.
Issues related to pharmacy benefit managers and the 340B Program.
Issues related to CMS coverage of anti-obesity medications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GERIATRICS SOCIETY via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Physician reimbursement reductions, sequestration issues, and incentives for advanced alternative payment model participation.
Support for geriatric workforce enhancement and academic career award programs and basic and clinical research on medical complexity and health issues affecting older Americans at the NIA; policy issues related to the health care workforce and the federal response to the COVID-19 virus; and policy issues related to COVID-19 pandemic preparedness, telehealth, and primary care incentive payments.
Funding for geriatrics clinical research and training at the Department of Veterans Affairs (VA) Office of Research & Development (ORD); funding for research programs at the National Institute on Aging (NIA); and funding for geriatric workforce and academic career award programs at the Health Resources and Services Administration (HRSA).
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to accreditation for telehealth and mental health parity.
Issues related to accreditation for mental health parity, as well as compliance with federal mental health parity laws and regulations, including the Mental Health Parity and Addiction Equity Act (MHPAEA - Public Law No: 110-343).
Issues related to accreditation for telehealth and mental health parity. Also, issues related to pharmacy benefit managers (PBMs) and specialty pharmacies.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing.
Issues related to Medicare coverage of multi-cancer early detection screening tests, including the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407 & S. 2085).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDUCTIVEHEALTH INFORMATICS via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to disease surveillance and pandemic preparedness.
Issues related to disease surveillance and pandemic preparedness, and the Pandemic All-Hazards Preparedness (PAHPA) reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVOGEN via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to domestic manufacturing of pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues and legislation related to (1) Medicare coverage of anti-obesity medications (AOMs), and (2) the 340B drug pricing program.
Issues and legislation related to (1) Medicare coverage of anti-obesity medications (AOMs), and (2) the 340B drug pricing program.
ALVOGEN via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to domestic manufacturing of pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199).
Senate and House Appropriations Committees report language on nuclear medicine event reporting. Department of Defense Congressionally Directed Medical Research Programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN GERIATRICS SOCIETY via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Funding for geriatrics clinical research and training at the Department of Veterans Affairs (VA) Office of Research & Development (ORD); funding for research programs at the National Institute on Aging (NIA); and funding for geriatric workforce and academic career award programs at the Health Resources and Services Administration (HRSA).
Support for geriatric workforce enhancement and academic career award programs and basic and clinical research on medical complexity and health issues affecting older Americans at the NIA; policy issues related to the health care workforce and the federal response to the COVID-19 virus; and policy issues related to COVID-19 pandemic preparedness, telehealth, and primary care incentive payments.
INDUCTIVEHEALTH INFORMATICS via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to disease surveillance and pandemic preparedness, and the Pandemic All-Hazards Preparedness (PAHPA) reauthorization.
Issues related to disease surveillance and pandemic preparedness, and the Pandemic All-Hazards Preparedness (PAHPA) reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.
Issues related to R&D tax credits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
URAC, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to accreditation for telehealth and mental health parity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADAPTIVE BIOTECHNOLOGIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · first_quarter · Q1
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 (H.R. 2369).
Issues related to supporting research pertaining to Minimal Residual Disease (MRD) testing.
Issues related to Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to health care accreditation, mental health parity, and Medicare Advantage plans. Issues related to reforms to the Organ Procurement and Transplantation Network (OPTN), including the role of accreditation. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609) and the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] (H.R. 6610). Issues related to telehealth accreditation, including implementation of report language included in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)]. Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Issues related to health care accreditation, Medicare Advantage plans (including Medicare Advantage Special Needs Plans (SNP) reviews), telehealth, and mental health parity. Issues related to pharmacy benefit management services and specialty pharmacies, including accreditations of both, and the Pharmacists Fight Back in Medicare and Medicaid Act (H.R. 6609). Issues related to health care artificial intelligence accreditation, including report language included in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)].
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 and Senate Report 119-55. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to physician payment reform. Issues related to CMS reimbursement for radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to health care artificial intelligence accreditation, including congressional encouragement of HHS and ASTP/ONC to utilize accreditation to ensure responsible implementation and effective use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs on radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to telehealth accreditation, including congressional encouragement of HHS and HRSA to utilize telehealth accreditation to ensure high quality care for patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs on radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to telehealth accreditation, including congressional encouragement of HHS and HRSA to utilize telehealth accreditation to ensure high quality care for patients.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to telehealth accreditation, including congressional encouragement of HHS and HRSA to utilize telehealth accreditation to ensure high quality care for patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs on radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to telehealth accreditation, including congressional encouragement of HHS and HRSA to utilize telehealth accreditation to ensure high quality care for patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariffs on radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development (R&D) tax credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Senate and House Appropriations Committees report language on nuclear medicine event reporting. Issues related to the Department of Defense Congressionally Directed Medical Research Programs' Peer Reviewed Cancer Research Program, including pertaining to the Department of Defense Appropriations Act, 2025 (S. 4921; Senate Report 118-204).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086/S. 5141).
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act (H.R. 6815).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare reimbursement of radiopharmaceuticals and nuclear medicine and Medicare reimbursement of cardiac PET scans, including the Facilitating Innovative Nuclear Diagnostics (FIND) Act (H.R. 1199 / S. 1544).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
Issues pertaining to the utility and role of nuclear medicine as it relates to the goals of the White House's Cancer Moonshot. Additionally, issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to physician reimbursement reductions, sequestration issues, and incentives for advanced alternative payment model (AAPM) participation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to the utility and role of nuclear medicine as it relates to the goals of the White House's Cancer Moonshot. Additionally, issues related to coverage of molecular breast imaging (MBI), including under the Find It Early Act (H.R. 3086).
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to the utility of nuclear medicine at the Congressionally Directed Medical Research Programs, as related to the National Defense Authorization Act for Fiscal Year 2024 (H.R. 2670) and the National Defense Authorization Act for Fiscal Year 2024 (S. 2226).
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Physician reimbursement reductions, sequestration issues, and incentives for advanced alternative payment model participation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE